Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma?

Cancer

Volumn 78, Issue 5, 1996, Pages 1079-1084

  Ravery, Vincent ^a   Schmid, Hans Peter ^a   Toublanc, Marianne ^a   Boccon Gibod, Laurent ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

biopsy; cancer; prognosis; prostate

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA;

EID: 0029834010     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960901)78:5<1079::aid-cncr18>3.0.co;2-%23     Document Type: Article

References (19)

1. Hermanek P, Sobin LH. UISS - International Union Against Cancer TNM classification of malignant tumors. 4th ed. Heidelberg: Springer-Verlag, 1987:133.
2. Terris MK, Mcneal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992;148:829-32.
3. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-8.
4. Stamey TA, Mcneal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-41.
5. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Meulmans A, Toublanc M, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistant/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-6.
6. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
7. Humphrey PA, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995;75:1842-9.
8. Andriole GL, Ponas SH, Catalona WJ. The implication of focal well differentiated prostate cancer (CaP) in men with elevated serum PSA and palpably normal prostates [abstract]. J Urol 1992;147:442A.
9. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994;44:862-8.
10. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989;141:341-5.
11. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995;154:1074-7.
12. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995;26:223-9.
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
14. Bostwick DG, Cupp MR, Oesterling JE. Tumor volume in prostate cancer: correlation of needle biopsy and radical prostatectomy findings [abstract]. Mod Pathol 1993;6:70A.
15. Thomassen L, Tsuchiya K, True LD. Accuracy of needle biopsies in predicting tumor distribution in radical prostatectomies [abstract]. Mod Pathol 1993;6:70A.
16. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastases at radical prostatectomy. J Urol 1993;150:1845-50.
17. Stricker HJ, Ruddock LJ, Wan J, Belville WD. Detection of non-palpable prostate cancer. A mathematical and laboratory model. Br J Urol 1993;71:43-46.
18. Goto Y, Ohori M, Arakaw A. Distinguishing clinically important from unimportant prostate cancers before treatment: prelimary report. J Urol 1994;151:289A.
19. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478-81.